Editor's Highlights—June 2026
International Journal of Dermatology · 2026-06 · 65 (6) · 1131-1132
DOI: 10.1111/ijd.70463 ↗Kurz gefasst
Editorial in der Zeitschrift International Journal of Dermatology, online erschienen am 02.05.2026. Verfasst von Lajos Kemény. Beteiligte Einrichtung: Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Psoriasis, Hidradenitis Suppurativa. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Major advances have broadened the therapeutic landscape of inflammatory skin diseases. In psoriasis, alongside the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib, the United States Food and Drug Administration (FDA) has approved the first oral interleukin‐23 (IL‐23) receptor antagonist peptide, icotrokinra. In atopic dermatitis, new data have emerged on stapokibart, an interleukin‐4 receptor alpha subunit (IL‐4Rα) inhibitor introduced in China. In hidradenitis suppurativa, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) are also gaining increasing attention as adjunctive therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
ORCID-Profile: Lajos Kemény
Zitieren
APA
Kemény, L. (2026). Editor's Highlights—June 2026. International Journal of Dermatology, 65(6), 1131-1132. https://doi.org/10.1111/ijd.70463
Vancouver
Kemény L. Editor's Highlights—June 2026. International Journal of Dermatology. 2026;65(6):1131-1132. doi:10.1111/ijd.70463
BibTeX
@article{Kemny2026,
author = {Kemény, Lajos},
title = {Editor's Highlights—June 2026},
journal = {International Journal of Dermatology},
year = {2026},
volume = {65},
number = {6},
pages = {1131--1132},
doi = {10.1111/ijd.70463}
}
EUVIMED